



ACIP Human Rabies Prevention Work Group

Sharon Frey, MD

Saint Louis University School of Medicine

Advisory Committee on Immunization Practices

October 23, 2019

Work Group Members

ACIP Members

Sharon Frey (chair)

Lynn Bahta

José R. Romero

Liaison Representatives

AAP- Elizabeth Bennett

AAFP- James Stevermer

NACCHO- Matt Zahn

APhA- Karl Hess

NACI- Julie Emili and Linlu Zhao

FDA- Paula Agger and Robin Levis

NASPHV- Katie Brown and Sally Slavinski

APHL-Michael Pentella

Travel medicine- David Shlim

Additional Subject Matter Experts

Susan Moore

Deborah Briggs

CDC

*Rabies Work Group leads – Jesse Blanton
and Agam Rao*

*Division of Global Migration and
Quarantine- Kristina Angelo*

Immunization Safety Office – Pedro Moro

Acknowledgements

CDC Technical Work Group and Subject Matter Experts

Brett Petersen

Ryan Wallace

James Ellison

Sathesh Panayampalli

Anna Mandra

Jesse Bonwitt

Erin Whitehouse


Terms of Reference Abbreviated

- Determine the epidemiology and burden of rabies exposures and PreP and PEP administration in the United States
- Evaluate and revise recommendations as needed for vaccination schedules, route and site of PreP and PEP, and cost-effectiveness
- Consider evidence generated to inform the rabies recommendations of other global organizations
- Review rabies exposure risk and risk assessment guidelines for the general population and by occupational and recreational groups

Terms of Reference Continued

- Evaluate serological and monitoring recommendations including whether recommendations should differ depending on the degree of rabies risk for a person and whether adequate antibody titers are needed to confirm immunization
- Consider whether recommendations should differ for healthy adults compared to immunocompromised persons and pregnant women
- Update recommendations with information about the 2 rabies immune globulin products approved by the US FDA during 2018
- Identify areas in need of further research for informing future vaccine and immune globulin recommendations

Timeline (Subject to Change)



Tentative Plan for Presentations

- October 2019 – Background and introduction to PrEP issues
- February 2020
 - Detailed PrEP data including GRADE table
 - Introduction to PEP issues
- June 2020
 - Vote for PrEP topics
 - More detailed presentations about PEP
- October 2020
 - More detailed presentations about PEP vs. vote on PEP issues

Note: Current Rabies Vaccine and Immune Globulin Shortages

- The shortages should not impact patient care. Vaccine and RIG available for every patient who needs it. No modification to current practices.
- Vaccine
 - RabAvert (GlaxoSmithKline): available directly from the manufacturer
 - Imovax[®] (Sanofi Pasteur): Currently unavailable but expected to be available late Oct / early Nov
- RIG
 - Imogam[®] (Sanofi Pasteur): available directly from manufacturer
 - Kedrab[™] (Kedrion Biopharma) and HyperRab[®] (Grifols): unchanged availability and no difficulties filling gap from Imogam

October 21, 2019 GlaxoSmithKline Announcement

- GSK divesting rabies vaccine (RabAvert in U.S.) to Bavarian Nordic
- Vaccine will continue to be manufactured primarily at GSK's Marburg, Germany site until full production is transferred to Bavarian Nordic
- No immediate impact to vaccine supply

Overview of Today's Session

- Background - *Dr. Agam Rao (CDC/NCEZID)*
- Introduction to rabies PrEP schedule and serological monitoring by risk category in healthy nonpregnant persons and special populations - *Dr. Jesse Blanton (CDC/NCEZID)*

Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

